/ BAILLIE GIFFORD /
The benefits will be seen in the standard of care in
cancer in the next five years, and in broader use in
applying testing and treatments, at a pace we have only
seen in the technology sector before
their most valuable commodity;
certainly the possibilities in data
analysis are opening up rapidly.
Companies such as Splunk, which
specialises in analysing big data,
and Palantir, which analyses
data for security implications
for governments and large
corporations, are among the
potential winners in this field,
Slater believes.
Elsewhere, as part of the current
technological revolution, genomic
science and gene therapies are
taking us closer to the age of
personalised medicine. “Illumina,
which makes genetic testing
kits, has driven down the cost of
sequencing the human genome
by a thousand-fold in a decade —
astonishing,” Slater observes. He
adds that the benefits will be seen “in
the standard of care in cancer in the
next five years, and in broader use in
applying testing and treatments, and
at a pace we have only seen in the
technology sector before”.
TRANSFORMING MEDICINE
Illumina, whose share price
increase has helped it to become
trustnetdirect.com
17